Data Will Highlight Potential Advantages of Rezafungin for the
Treatment and Prevention of Invasive Fungal Infections
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that Dr. Taylor Sandison, chief medical officer, will present
clinical efficacy and safety data for the company’s lead antifungal
rezafungin for the treatment and prevention of invasive fungal
infections at two upcoming, global infectious disease conferences.
Abstracts highlighting rezafungin data have been accepted at The 20th
International Immunocompromised Host Society (ICHS) Symposium in Athens,
Greece, taking place June 17-19, 2018, and The International Society for
Human and Animal Mycology (ISHAM) Congress in Amsterdam, taking place in
The Netherlands, June 30-July 4, 2018.
The ICHS Symposium is an international, multi-disciplinary forum for
scientific and clinical interchange to improve understanding and
management of the immunocompromised host. The ISHAM Congress is held
every three years and provides clinicians, scientists and students an
opportunity to meet at an international forum dedicated solely to the
study of medical mycology.
Presentation details are as follows:
ICHS Symposium
Session: New Antifungals
Title: Rezafungin, a Novel
Echinocandin for Treatment and Prevention of Invasive Fungal Infections
(IFIs)
Date and time: Sunday, June 17 from 12:00 p.m.
– 1:00 p.m. EEST
Presenter: T. Sandison
Location: Hotel
Divani Acropolis (Erectheion Room), Athens, Greece
ISHAM Congress
Session: Antifungal Pipeline
Title: Rezafungin, a
Novel Echinocandin for Treatment and Prevention of Invasive Fungal
Infections (IFIs)
Date and time: Monday, July 2 from 10:30
a.m. – 12:00 p.m. CEST
Presenter: T. Sandison
Location:
RAI Amsterdam, Europaplein
Copies of these presentations will be available on the Cidara website
following the meeting: www.cidara.com
About Rezafungin
Rezafungin is a novel antifungal echinocandin being developed as a
once-weekly, high-exposure therapy for the treatment and prevention of
serious invasive fungal infections. Cidara Therapeutics recently
announced topline results from its Phase 2 STRIVE clinical trial (Part
A) evaluating the safety, tolerability and efficacy of
once-weekly dosing of rezafungin compared to once-daily dosing of
caspofungin in patients with candidemia and/or invasive candidiasis. The
data showed that once-weekly intravenous dosing of rezafungin was
generally well tolerated and safe in patients with candidemia and/or
invasive candidiasis. Based on these data, the company plans to initiate
Phase 3 pivotal trials in the treatment of candidemia and invasive
candidiasis and the prophylaxis of invasive fungal infections.
About Invasive Fungal Infections
Invasive fungal infections (IFIs) represent a serious threat to millions
of patients worldwide, resulting in more than 1.5 million deaths
annually and mortality rates ranging from 15 to 65 percent. These
infections continue to be a global health issue, especially for
critically ill patients in hospitals and patients with compromised
immune systems, including cancer and transplant patients. Approximately
90 percent of IFI-related deaths are associated with Candida, Aspergillus
and Pneumocystis.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate,
formerly known as CD101 IV, through clinical trials. Rezafungin has
improved pharmacokinetics compared to existing echinocandins and the
potential for expanded utility across patient settings. It is the only
once-weekly product candidate in development for the treatment and
prevention of life-threatening invasive fungal infections. The company’s
Phase 2 STRIVE clinical trial of rezafungin met its primary safety and
efficacy objectives, and provides support for Cidara to initiate Phase 3
pivotal trials in the treatment of candidemia and invasive candidiasis,
and the prophylaxis of invasive fungal infections. Cidara also is
leveraging its novel Cloudbreak™ platform to develop antibody-drug
conjugates for the treatment of multi-drug resistant Gram-negative
bacterial infections. Cloudbreak is the first immunotherapy discovery
platform designed specifically to create compounds that directly kill
pathogens and also direct a patient’s immune cells to attack and
eliminate bacterial, fungal or viral pathogens. Cidara is headquartered
in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, the potential for rezafungin to successfully treat or prevent
invasive fungal infections and represent an improvement over current
approaches, and Cidara’s ability to successfully develop rezafungin.
Risks that contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were
made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005151/en/
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl
Managing
Director
858-356-5932
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran
615-414-8668
ChristyCurran@sambrown.com
